Nanobiotix S.A. (NBTX) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nanobiotix S.A. (NBTX) has outperformed UroGen Pharma (URGN) over the past year, gaining 26.6% versus a gain of 6.9%. Over five years, NBTX leads with a +214.0% price change compared with +127.8% for URGN. UroGen Pharma is the larger company by market cap ($1.36 billion vs $1.35 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBTX | URGN |
|---|---|---|
| Share price | $26.50 | $27.65 |
| Market cap | $1.35B | $1.36B |
| 1-day change | -2.98% | -12.86% |
| YTD return | +14.62% | +18.06% |
| 1-year return | +26.61% | +6.88% |
| 5-year return | +213.98% | +127.76% |
| Forward P/E | — | 11.08 |
| EPS (TTM) | $-1.27 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | — | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $57.14 | $50.81 |
| 52-week low | $19.14 | $16.50 |
| Distance from 52-week high | -53.62% | -45.58% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +101.06% | +119.57% |
| Average volume | 148.94K | 1.11M |
| Shares outstanding | 50.95M | 49.05M |
| Employees | 98 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NBTX has outperformed URGN by 19.7 percentage points over the past year.
About Nanobiotix S.A.
NBTX stock →Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
NBTX vs URGN FAQ
Which is bigger, Nanobiotix S.A. or UroGen Pharma?
UroGen Pharma (URGN) is larger, with a market capitalization of $1.36B compared with $1.35B for Nanobiotix S.A. (NBTX).
Which stock has performed better over the past year, NBTX or URGN?
NBTX returned +26.61% over the past 12 months, compared with +6.88% for URGN (price return, excluding dividends). Past performance does not predict future results.
Are Nanobiotix S.A. and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.